Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Newron Pharmaceuticals S.p.A.

Newron Announces Approval for Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-resistant Schizophrenia (TRS)
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Newron Presents 2024 Financial Results and Provides 2025 Outlook
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Newron proposes renowned biopharma company founder and entrepreneur Dr. Chris Martin for election as Independent Chairman
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Newron Pharmaceuticals to Participate in a Fireside Chat at the 37th Annual ROTH Conference
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Newron and Myung In Pharm Announce License Agreement for evenamide in South Korea
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Newron and EA Pharma (A Subsidiary of Eisai Co., Ltd.) Announce License Agreement for Evenamide in Japan and Other Asian Territories
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Newron presents H1 2024 results and provides business update
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Newron Pharmaceuticals Reports on Its 2024 Investor Day in New York City
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Newron Pharmaceuticals Will Host Its 2024 Investor Day on June 25 in New York City
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Newron Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Newron Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Newron Presents 2023 Financial Results and Provides 2024 Outlook
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Newron Reports Exceptional One-year Results of Study 014/15 With Evenamide in Treatment-resistant Schizophrenia (TRS)
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Newron Completes Enrollment of Schizophrenia Patients in Potentially Pivotal Study 008A With Evenamide
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Newron TRS Study 6 Months’ Results: Evenamide Substantially Improves Patients to an Extent That They No Longer Meet Protocol Entry Criteria
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Newron to Present Three Posters on Its Clinical Program Evaluating Evenamide in the Treatment of Schizophrenia at the 36th European College of Neuropsychopharmacology Congress
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Newron Appoints Margarita Chavez as Board Advisor
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Newron Announces H1 2023 Results and Provides R&D Update
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Newron Presents Exciting New Data From Study 014/015 at CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Newron to Present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Newron Announces Senior Management Team Changes
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Newron Presents Six-Month Interim Data From the First 100 Patients Randomized in Study 014/015 at the 31st European Congress of Psychiatry
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Newron Reports Compelling Topline Results From All Patients in Study 014, Its Phase II Clinical Trial Evaluating Evenamide as Add-on Therapy for Treatment-resistant Schizophrenia
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Newron to present at the 31st European Congress of Psychiatry
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Newron Announces 2022 Financial Results and Provides Outlook For 2023
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Newron Reports Striking One-Year Interim Efficacy Results From Its Phase II Clinical Trial Evaluating Evenamide as Add-On Therapy for Patients With Treatment-Resistant Schizophrenia
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia
From Newron Pharmaceuticals S.p.A.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.